432 results on '"Domenicali, M."'
Search Results
2. Human Albumin: An Important Bullet Against Bacterial Infection in Patients with Liver Cirrhosis?
- Author
-
Bernardi, M., Domenicali, M., Caraceni, P., and Vincent, Jean-Louis, editor
- Published
- 2015
- Full Text
- View/download PDF
3. Asymptomatic and symptomatic deep venous thrombosis in hospitalized acutely ill medical patients. risk factors and therapeutic implications
- Author
-
Loffredo L., Vidili G., Sciacqua A., Cogliati C., Di Giulio R., Bernardini S., Ciacci P., Pietrangelo A., Orlando F., Paraninfi A., Boddi M., Di Minno G., Falsetti L., Lodigiani C., Santoliquido A., Ettorre E., Pignatelli P., Arezzo M. F., Gutu E., Harenberg J., Violi F., Casciaro M. A., Morelli S., Accapezzato D., Rossi E., Palumbo I. M., Pannunzio A., Fallarino A., Maggio E., Bocchini V. P., Gioia C., Izzo R., Luongo R., Cosenza M., Bisciglia M. F., Battaglia S., Pirillo L. S., Capozza A., Summa M. L., Armentaro G., Volpentesta M., Rullo R., Baldinia L., Arienti V., Meloni P. L., Sauchella A., Melis S., Berria M., Solinas B., Vilardi L., Sarobba P., Pisanu M., Mangatia P., Cringoli M., Blanca D., Casella F., Vegetti A., Crociani A., Donnarumma E., Pacciani G., Rovereto R., Lunardi S., Tufano A., Pacetti V., Domenicali M., Leopoldo P., Ceci F., Loffredo, L., Vidili, G., Sciacqua, A., Cogliati, C., Di Giulio, R., Bernardini, S., Ciacci, P., Pietrangelo, A., Orlando, F., Paraninfi, A., Boddi, M., Di Minno, G., Falsetti, L., Lodigiani, C., Santoliquido, A., Ettorre, E., Pignatelli, P., Arezzo, M. F., Gutu, E., Harenberg, J., Violi, F., Casciaro, M. A., Morelli, S., Accapezzato, D., Rossi, E., Palumbo, I. M., Pannunzio, A., Fallarino, A., Maggio, E., Bocchini, V. P., Gioia, C., Izzo, R., Luongo, R., Cosenza, M., Bisciglia, M. F., Battaglia, S., Pirillo, L. S., Capozza, A., Summa, M. L., Armentaro, G., Volpentesta, M., Rullo, R., Baldinia, L., Arienti, V., Meloni, P. L., Sauchella, A., Melis, S., Berria, M., Solinas, B., Vilardi, L., Sarobba, P., Pisanu, M., Mangatia, P., Cringoli, M., Blanca, D., Casella, F., Vegetti, A., Crociani, A., Donnarumma, E., Pacciani, G., Rovereto, R., Lunardi, S., Tufano, A., Pacetti, V., Domenicali, M., Leopoldo, P., and Ceci, F.
- Subjects
anticoagulants ,asymptomatic deep venous thrombosis ,compression ultrasound ,Anticoagulant ,medical patient ,Hematology ,Asymptomatic deep venous thrombosi ,Deep venous thrombosi ,deep venous thrombosis - Abstract
Background Acutely ill medical patients experience deep venous thrombosis (DVT) during the hospitalization, however the time course of DVT is still unclear. Objectives To evaluate risk factors in acutely ill hospitalized medical patients for proximal asymptomatic DVT (ADVT) and symptomatic DVT (SDVT) at admission and discharge. Patients/Methods In this prospective observational study, consecutive acutely ill medical patients (hospitalized mainly for acute medical disease as infections, neoplasm, anemia, heart failure) underwent compression ultrasonography (CUS) of proximal lower limb veins within 48 h from admission and at discharge to diagnose ADVT and SDVT. Covid-19 patients, anticoagulant therapy, surgical procedures, acute SDVT, and acute pulmonary embolism, were exclusion criteria. Biographical characteristics at hospitalization, D-Dimer (assessed by ELISA)) and DD-improve score. Results Of 2,100 patients (1002 females, 998 males, age 71 ± 16 years) 58 (2.7%) had proximal ADVT at admission. Logistic regression analysis showed that age, and active cancer were independently associated with ADVT at admission. The median length of hospitalization was 10 days [interquartile range: 6–15]. During the hospital stay, 6 patients (0.3%) with a negative CUS at admission experienced DVT (2 SDVT and 4 ADVT). In the subgroup of patients (n = 1118), in whom D-dimer was measured at admission, D-Dimer and IMPROVE-DD score were associated with ADVT at admission (n = 37) and with all DVT (n = 42) at discharge. ROC curve defined an IMPROVE-DD score of 2.5 as the optimal cut-off for discriminating patients with and without thrombotic events. Conclusions We provide evidence of early development of ADVT in unselected acutely ill medical patients suggesting the need of investigating patients by CUS immediately after hospital admission (within 48 h). Advanced age, active cancer, known thrombophilia and increased IMPROVE-DD score may identify patients at risk. The benefit of anticoagulation needs to be investigated in patients with these specific risk factors and negative CUS at admission. Trial registration NCT03157843.
- Published
- 2022
4. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?
- Author
-
Foschi F. G., Domenicali M., Giacomoni P., Dall'Aglio A. C., Conti F., Borghi A., Bevilacqua V., Napoli L., Mirici F., Cucchetti A., Ercolani G., Gardini A. C., Bellentani S., Gastaldelli A., Giuffre M., Tiribelli C., Bedogni G., BEDOGNI, GIORGIO, Foschi F.G., Domenicali M., Giacomoni P., Dall'Aglio A.C., Conti F., Borghi A., Bevilacqua V., Napoli L., Mirici F., Cucchetti A., Ercolani G., Gardini A.C., Bellentani S., Gastaldelli A., Giuffre M., Tiribelli C., and Bedogni G.
- Subjects
Liver Cirrhosis ,Male ,Percentile ,Cross-sectional study ,Epidemiology ,Specialties of internal medicine ,Chronic liver disease ,Gastroenterology ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,Medicine ,Metabolic Syndrome ,education.field_of_study ,Elasticity imaging technique ,Alanine Transaminase ,gamma-Glutamyltransferase ,General Medicine ,Middle Aged ,RC581-951 ,030220 oncology & carcinogenesis ,Elasticity Imaging Techniques ,Biomarker (medicine) ,Female ,030211 gastroenterology & hepatology ,Fatty Liver, Alcoholic ,Adult ,medicine.medical_specialty ,Population ,Liver fibrosis ,03 medical and health sciences ,Internal medicine ,BAAT ,Humans ,Clinical significance ,Aspartate Aminotransferases ,Obesity ,education ,Hepatology ,Platelet Count ,business.industry ,Cholesterol, HDL ,Cholesterol, LDL ,Biomarker ,Overweight ,medicine.disease ,business ,Transient elastography ,Biomarkers - Abstract
Introduction and objectives Surrogate biomarkers of liver fibrosis developed in tertiary care are increasingly used in general populations. We evaluated the association between liver stiffness (LS) and five continuous (AST/ALT, APRI, Forns Index, FIB-4, GGT) and two discrete biomarkers (BARD, BAAT) in a general population. Patients and methods 636 (29%) of the 2159 citizens of the Bagnacavallo Study had LS measured by transient elastography. Using linear regression with univariate multiple imputation, we evaluated the association of LS with the above biomarkers in the total sample of 2159 citizens. Results The mean change of LS between the 5th and 95th internal percentile of any continuous biomarker was ≤1 kPa. The mean change of LS between scores 0 and 3 of BARD and scores 0 and ≥3 of BAAT was >1 kPa but of doubtful clinical relevance. Conclusion We found a modest association between LS and seven biomarkers of liver fibrosis in a general population.
- Published
- 2020
5. Mortality risk in a population of patients treated for gambling disorders: results of a follow-up study
- Author
-
Pavarin, R. M., Domenicali, M., Marani, S., Turino, E., Caputo, F., Pavarin R.M., Domenicali M., Marani S., Turino E., and Caputo F.
- Subjects
Male ,Gambling disorders ,Mental Disorders ,Cancer, Gambling disorders, suicide, mortality risk ,Gambling disorder ,NO ,Cohort Studies ,Suicide ,Cause of Death ,Gambling ,Humans ,Female ,Mortality risk ,Cancer ,Aged ,Follow-Up Studies - Abstract
Aims. To examine mortality risk and causes of death in a cohort of a population of patients treated for gambling disorders in northern Italy from 1992 to 2019. Methods. Cohort study. Results. Half of the patients were diagnosed with psychiatric disorders, substance use disorder or alcohol dependence. The excess mortality compared to the general population (SMR) was 1.16 (0.85-1.58), more elevated among females aged 40 to 59 and males aged 20 to 29. Females had higher SMRs for all cancers and suicide; males for malignant neoplasm of liver, of lung, of prostate, and of bladder. Conclusions. Despite patients increasing, subjects who most turn to the services are the most serious ones, in older age, with comorbid mental disorders and with a compromised health status. This is reflected in the high risk of death for all cancers.
- Published
- 2021
6. Development and Internal Validation of Fatty Liver Prediction Models in Obese Children and Adolescents
- Author
-
Bedogni G., Tamini S., Caroli D., Cicolini S., Domenicali M., Sartorio A., BEDOGNI, GIORGIO, Bedogni G., Tamini S., Caroli D., Cicolini S., Domenicali M., and Sartorio A.
- Subjects
medicine.medical_specialty ,obesity ,Waist ,Adolescent ,Aspartate transaminase ,lcsh:Medicine ,Logistic regression ,Gastroenterology ,Article ,03 medical and health sciences ,diagnostic techniques and procedures ,0302 clinical medicine ,Insulin resistance ,children ,Interquartile range ,Internal medicine ,medicine ,cross-sectional study ,030212 general & internal medicine ,adolescents ,fatty liver ,biology ,business.industry ,Fatty liver ,lcsh:R ,nutritional and metabolic diseases ,Diagnostic techniques and proce-dure ,General Medicine ,medicine.disease ,Alanine transaminase ,biology.protein ,030211 gastroenterology & hepatology ,business ,Body mass index - Abstract
To develop predictive models of fatty liver (FL), we performed a cross-sectional retrospective study of 1672 obese children with a median (interquartile range) age of 15 (13–16) years. The outcome variable was FL diagnosed by ultrasonography. The potential predictors were: (1) binary: sex, (2) continuous: age, body mass index (BMI), waist circumference (WC), alanine transaminase (ALT), aspartate transaminase, gamma-glutamyltransferase, glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), HDL-cholesterol, LDL-cholesterol, triglycerides, mean arterial pressure, uric acid, and c-reactive protein, (3) ordinal: Pubertal status. Bootstrapped multivariable logistic regression with fractional polynomials was used to develop the models. Two models were developed and internally validated, one using BMI and the other using WC as the anthropometric predictor. Both models included ALT, HOMA-IR, triglycerides, and uric acid as predictors, had similar discrimination (c-statistic = 0.81), and were similarly well calibrated as determined by calibration plots. These models should undergo external validation before being employed in clinical or research practice.
- Published
- 2021
7. Pulmonary artery thrombosis in COVID-19 patients
- Author
-
Graziani, A., Domenicali, M., Zanframundo, G., Palmese, F., Caroli, B., and Graziani, L.
- Published
- 2021
- Full Text
- View/download PDF
8. Identification of harmful drinking in subjects who have had their driving license suspended due to alcohol use: a retrospective Italian study
- Author
-
Caputo F., Pavarin R. M., Lungaro L., Minarini A., Vigna-Taglianti F., Brambilla R., Sanchini S., Zoli E., Noventa A., Domenicali M., Vignoli T., Patussi V., Testino G., Scafato E., de Giorgio R., Zoli G., Caputo F., Pavarin R.M., Lungaro L., Minarini A., Vigna-Taglianti F., Brambilla R., Sanchini S., Zoli E., Noventa A., Domenicali M., Vignoli T., Patussi V., Testino G., Scafato E., de Giorgio R., and Zoli G.
- Subjects
Adult ,Automobile Driving ,Alcohol Drinking ,Alcohol use disorder ,Drinking ,Driving ,Harmful drinking ,Alcoholism ,Biomarkers ,Humans ,Italy ,Licensure ,Middle Aged ,Retrospective Studies ,Surveys and Questionnaires ,NO - Abstract
OBJECTIVE: Early identification of Harmful Drinking (HD) is difficult, and underestimated. The aim of our retrospective study was to investigate the presence of HD in a population of subjects who had their driving license suspended due to driving under the influence of alcohol. MATERIALS AND METHODS: We retrospectively recruited 979 subjects. During the first appointment (T0), clinical and laboratory characteristics of patients were evaluated, and the AUDIT questionnaire was administered. Two groups were then defined: Harmful Drinking (HD) and non-HD, and all subjects underwent a brief interview for 5-10 minutes before being assigned to a group. RESULTS: 95.9% of our sample were identified as non-HD, whereas 4.1% of them were HD; twenty-one (2.1%) of the HD underwent a control appointment (T1), and 17 (1.7%) of them were diagnosed with alcohol use disorder (AUD); there was a statistically significant reduction in mean daily alcohol intake (p
- Published
- 2020
9. Pulmonary artery thrombosis in home patient with a mild COVID-19 disease Tromboza arterei pulmonare la pacient cu boala COVID 19 forma usoara aflat la domiciliu
- Author
-
Graziani A., Domenicali M., Zanframundo G., Palmese F., Caroli B., Cataleta P., Graziani L., Graziani A., Domenicali M., Zanframundo G., Palmese F., Caroli B., Cataleta P., and Graziani L.
- Subjects
interstitial pneumonia ,pulmonary artery thrombosis ,COVID-19 ,d-dimer - Abstract
COVID-19 has been described as the cause for a proinflammatory and hypercoagulable state that induces thrombotic vascular lesions and, in more severe cases, disseminated intravascular coagulation. Increased values of d-dimers are related to the severity of the disease and are associated with worst prognosis. Intensive care studies reported an increased risk of pulmonary embolism and venous thrombosis diseases in COVID-19 compared with the historical control group even in patients who underwent the low-molecular-weight heparin (LWMH) prophylaxis. Patients with COVID-19 who have a stable clinical condition do not require hospitalisation and are treated at home with symptomatic therapy. LWMH is reserved for those with reduced mobility. In this case report, we describe a COVID-19 patient with pulmonary artery thrombosis treated at home.
- Published
- 2020
10. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia
- Author
-
Caraceni, P., Pertosa, A.M., Giannone, F., Domenicali, M., Grattagliano, I., Principe, A., Mastroleo, C., Perrelli, M.G., Cutrin, J., Trevisani, F., Croci, T., and Bernardi, M.
- Subjects
Reperfusion injury -- Care and treatment ,Reperfusion injury -- Complications and side effects ,Reperfusion injury -- Research ,Septic shock -- Care and treatment ,Septic shock -- Research ,Cannabinoids -- Physiological aspects ,Cannabinoids -- Research ,Health - Published
- 2009
11. Could inflammatory indices and metabolic syndrome predict the risk of cancer development? Analysis from the bagnacavallo population study
- Author
-
Rimini, M., Casadei-Gardini, A., Ravaioli, A., Rovesti, G., Conti, F., Borghi, A., Dall'Aglio, A. C., Bedogni, G., Domenicali, M., Giacomoni, P., Tiribelli, C., Bucchi, L., Falcini, F., Foschi, F. G., Gastaldelli, A., Ercolani, G., Cucchetti, A., Dazzani, F., Bevilacqua, V., Napoli, L., Mirici, F., Bellentani, S., Lanzi, A., Saini, G., Bernardi, M., Andreone, P., and Stefanini, G. F.
- Subjects
Breast cancer ,Cancer incidence ,Colon cancer ,Inflammatory indices ,Lung cancer ,Metabolic Syndrome ,NLR ,PLR ,SII - Published
- 2020
12. Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury
- Author
-
Caraceni, P., Giannone, F., Catani, L., Talarico, S., Pertosa, A.M., Domenicali, M., Fogli, M., Principe, A., Trevisani, F., Baccarani, M., Bernardi, M., and Lemoli, R.M.
- Published
- 2007
- Full Text
- View/download PDF
13. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors
- Author
-
Domenicali, M., Ros, J., Fernandez-Varo, G., Cejudo-Martin, P., Crespo, M., Morales-Ruiz, M., Briones, A.M., Campistol, J-M., Arroyo, V., Vila, E., Rodes, J., and Jimenez, W.
- Subjects
Vasodilators -- Patient outcomes ,Proteins -- Research ,Liver cirrhosis -- Drug therapy ,Rats as laboratory animals -- Research ,Cannabinoids -- Drug therapy ,Arteries -- Drug therapy ,Mesentery ,Health - Published
- 2005
14. Adaptation of subcellular glutathione detoxification system to stress conditions in choline-deficient diet induced rat fatty liver
- Author
-
Grattagliano, I., Caraceni, P., Portincasa, P., Domenicali, M., Palmieri, V.O., Trevisani, F, Bernardi, M, and Palasciano, G.
- Published
- 2003
- Full Text
- View/download PDF
15. A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection
- Author
-
Cassini, R., De Mitri, M. S., Gibellini, D., Urbinati, L., Bagaglio, S., Morsica, G., Domenicali, M., Verucchi, G., and Bernardi, M.
- Published
- 2013
- Full Text
- View/download PDF
16. Doxorubicin coupled to lactosaminated albumin: Effects on rats with liver fibrosis and cirrhosis
- Author
-
Di Stefano, G., Fiume, L., Domenicali, M., Busi, C., Chieco, P., Kratz, F., Lanza, M., Mattioli, A., Pariali, M., and Bernardi, M.
- Published
- 2006
- Full Text
- View/download PDF
17. Technical Aspects of Portal Vein Arterialization for Acute Liver Failure: From Rat Lab to Man
- Author
-
Nardo, B., Puviani, L., Caraceni, P., Montalti, R., Pacilè, V., Bertelli, R., Beltempo, P., Cavallari, G., Pariali, M., Angiolini, G., Domenicali, M., Neri, F., Prezzi, D., Tsivian, M., Chieco, P., and Cavallari, A.
- Published
- 2006
- Full Text
- View/download PDF
18. Successful Treatment of CCL 4-Induced Acute Liver Failure With Portal Vein Arterialization in the Rat
- Author
-
Nardo, B., Puviani, L., Caraceni, P., Pacilè, V., Bertelli, R., Beltempo, P., Cavallari, G., Chieco, P., Pariali, M., Pertosa, A.M., Angiolini, G., Domenicali, M., Neri, F., Tsivian, M., Bernardi, M., and Cavallari, A.
- Published
- 2006
- Full Text
- View/download PDF
19. Impaired tuftsin activity in cirrhosis: Relationship with splenic function and clinical outcome. (Liver Disease)
- Author
-
Trevisani, F., Castelli, E., Foschi, F.G., Parazza, M., Loggi, E., Bertelli, M., Melotti, C., Domenicali, M., Zoli, G., and Bernardi, M.
- Subjects
Spleen ,Liver cirrhosis -- Complications and side effects ,Health - Abstract
Background: Cirrhotic patients show increased susceptibility to bacterial infections, It is not known whether tuftsin deficiency, which is associated with an increased incidence of infections in many disease states, is [...]
- Published
- 2002
20. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma
- Author
-
Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F, Bolondi L, Biselli M, Bucci L, Caraceni P, Cucchetti A, Domenicali M, Venerandi L, Giacomin A, Maddalo G, Pozzan C, Vani V, Poggio PD, Olmi S, Balsamo C, Vavassori E, Benvegnù L, Cappelli A, Golfieri R, Mosconi C, Renzulli M, Bosco G, Roselli P, Dell'Isola S, Ialungo AM, Bruzzone L, Picciotto A, Marenco S, Risso D, Sammito G, Savarino V, Cammà C, Maida M, Costantino A, Barcellona MR, Affronti A, Mega A, Rinninella E, Mismas V, Cappa FM, Dall'Aglio AC, Feletti V, Lanzi A, Neri E, Stefanini GF, Tamberi S, Missale G, Porro E, Guarino M, Gemini S, Schiadà L, for the Italian LiverCancer (ITA. LI. CA) group, Donatella Magalotti, Carla Serra, Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Felder M, Morisco F, Gasbarrini A, Baroni GS, Foschi FG, Biasini E, Masotto A, Virdone R, Bernardi M, Trevisani F, Bolondi L, Biselli M, Bucci L, Caraceni P, Cucchetti A, Domenicali M, Magalotti D, Serra C, Venerandi L, Giacomin A, Maddalo G, Pozzan C, Vani V, Poggio PD, Olmi S, Balsamo C, Vavassori E, Benvegnù L, Cappelli A, Golfieri R, Mosconi C, Renzulli M, Bosco G, Roselli P, Dell'Isola S, Ialungo AM, Bruzzone L, Picciotto A, Marenco S, Risso D, Sammito G, Savarino V, Cammà C, Maida M, Costantino A, Barcellona MR, Affronti A, Mega A, Rinninella E, Mismas V, Cappa FM, Dall'Aglio AC, Feletti V, Lanzi A, Neri E, Stefanini GF, Tamberi S, Missale G, Porro E, Guarino M, Gemini S, Schiadà L, Pecorelli, A., Lenzi, B., Gramenzi, A., Garuti, F., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Cabibbo, G., Felder, M., Morisco, F., Gasbarrini, A., Baroni, G. S., Foschi, F. G., Biasini, E., Masotto, A., Virdone, R., Bernardi, M., Trevisani, F., Bolondi, L., Biselli, M., Bucci, L., Caraceni, P., Cucchetti, A., Domenicali, M., Magalotti, D., Serra, C., Venerandi, L., Giacomin, A., Maddalo, G., Pozzan, C., Vani, V., Poggio, P. D., Olmi, S., Balsamo, C., Vavassori, E., Benvegnu, L., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Bosco, G., Roselli, P., Dell'Isola, S., Ialungo, A. M., Bruzzone, L., Picciotto, A., Marenco, S., Risso, D., Sammito, G., Savarino, V., Camma, C., Maida, M., Costantino, A., Barcellona, M. R., Affronti, A., Mega, A., Rinninella, E., Mismas, V., Cappa, F. M., Dall'Aglio, A. C., Feletti, V., Lanzi, A., Neri, E., Stefanini, G. F., Tamberi, S., Missale, G., Porro, E., Guarino, M., Gemini, S., Schiada, L., Pecorelli, Anna, Lenzi, Barbara, Gramenzi, Annagiulia, Garuti, Francesca, Farinati, Fabio, Giannini, Edoardo G, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Felder, Martina, Morisco, Filomena, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Foschi, Francesco G, Biasini, Elisabetta, Masotto, Alberto, Virdone, Roberto, Bernardi, Mauro, and Trevisani, Franco
- Subjects
Sorafenib ,Male ,Niacinamide ,medicine.medical_specialty ,Standard of care ,Carcinoma, Hepatocellular ,Antineoplastic Agents ,Gastroenterology ,Intermediate stage ,03 medical and health sciences ,0302 clinical medicine ,HCC ,BCLC-B ,Treatment ,Hepatology ,Internal medicine ,medicine ,Humans ,Chemoembolization, Therapeutic ,Propensity Score ,Aged ,Neoplasm Staging ,Retrospective Studies ,intermediate stage ,treatment ,business.industry ,Patient Selection ,Phenylurea Compounds ,Liver Neoplasms ,Settore MED/09 - MEDICINA INTERNA ,Standard of Care ,Middle Aged ,medicine.disease ,Survival Analysis ,Treatment Outcome ,Italy ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Propensity score matching ,Multivariate Analysis ,030211 gastroenterology & hepatology ,Female ,Liver function ,Liver cancer ,business ,medicine.drug - Abstract
Background and aims the Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumor burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while others could undergo curative treatments. This study assesses the treatment type performed in a large cohort of BCLC-B patients and its outcome. Methods retrospective analysis of 485 consecutive BCLC-B patients from the ITA.LI.CA database diagnosed with naive HCC after 1999. Patients were stratified by treatment. Results 29 patients (6%) were lost to follow-up before receiving treatment. Treatment distribution was: TACE (233, 51.1%), curative treatments (145 patients, 31.8%), sorafenib (18, 3.9%), other (39, 8.5%), best supportive care (BSC) (21, 4.6%). Median survival (95% CI) was 45 months (37.4-52.7) for curative treatments, 30 (24.7-35.3) for TACE, 14 (10.5-17.5) for sorafenib, 14 (5.2-22.7) for other treatments and 10 (6.0-14.2) for BSC (p
- Published
- 2017
21. Subtle changes of c-reactive protein and serum creatinine during the index hospitalization predict early readmission in patients with decompensated cirrhosis
- Author
-
Tufoni, M., primary, Zaccherini, G., additional, Bartoletti, M., additional, Baldassarre, M., additional, Antognoli, A., additional, Leoni, S., additional, Berardi, S., additional, Tamè, M., additional, Marconi, L., additional, Basigli, E., additional, Iannone, G., additional, Pratelli, D., additional, Domenicali, M., additional, Viale, P., additional, Trevisani, F., additional, and Caraceni, P., additional
- Published
- 2020
- Full Text
- View/download PDF
22. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study
- Author
-
Morisco, Filomena, Camera, Silvia, Guarino, Maria, Tortora, Raffaella, Cossiga, Valentina, Vitiello, Anna, Cordone, Gabriella, Caporaso, Nicola, Di Costanzo, Giovan Giuseppe, Zoli, M., Garuti, F., Neri, A., Piscaglia, F., Lenzi, B., Valente, M., Trevisani, F., Bolondi, L., Biselli, M., Caraceni, P., Cucchetti, A., Domenicali, M., Gramenzi, A., Magalotti, D., Serra, C., Venerandi, L., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Giannini, E. G., Brunacci, M., Moscatelli, A., Pellegatta, G., Savarino, V., Caturelli, E., Roselli, P., Lauria, V., Pelecca, G., Dell'Isola, S., Ialungo, A. M., Rastrelli, E., Cabibbo, G., Cammà, C., Attardo, S., Rossi, M., Cavani, G., Virdone, R., Affronti, A., Nardone, G., Felder, M., Mega, A., Ciccarese, F., Del Poggio, P., Olmi, S., Foschi, F. G., Bevilacqua, V., Dall'Aglio, A. C., Ercolani, G., Fiorini, E., Casadei Gardini, A., Lanzi, A., Mirici Cappa, F., Sacco, R., Mismas, V., Svegliati Barone, G., Schiadà, L., Farinati, F., Gazzola, A., Murer, F., Pozzan, C., Vanin, V., Rapaccini, G. L., de Matthaeis, N., Gasbarrini, A., Rinninella, E., Olivani, A., Missale, G., Biasini, E., Di Marco, M., Balsamo, C., Vavassori, E., Masotto, A., Marchetti, F., Valerio, M., Marra, F., Aburas, S., Campani, C., Dragoni, G., Borzio, F., Benvegnù, L., Festi, D., Marasco, Giovanni, Ravaioli, Federico, Morisco, Filomena, Camera, Silvia, Guarino, Maria, Tortora, Raffaella, Cossiga, Valentina, Vitiello, Anna, Cordone, Gabriella, Caporaso, Nicola, Di Costanzo, Giovan Giuseppe, Zoli, M., Garuti, F., Neri, A., Piscaglia, F., Lenzi, B., Valente, M., Trevisani, F., Bolondi, L., Biselli, M., Caraceni, P., Cucchetti, A., Domenicali, M., Gramenzi, A., Magalotti, D., Serra, C., Venerandi, L., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Giannini, E.G., Brunacci, M., Moscatelli, A., Pellegatta, G., Savarino, V., Caturelli, E., Roselli, P., Lauria, V., Pelecca, G., Dell'Isola, S., Ialungo, A.M., Rastrelli, E., Cabibbo, G., Cammà, C., Attardo, S., Rossi, M., Cavani, G., Virdone, R., Affronti, A., Nardone, G., Felder, M., Mega, A., Ciccarese, F., Del Poggio, P., Olmi, S., Foschi, F.G., Bevilacqua, V., Dall'Aglio, A.C., Ercolani, G., Fiorini, E., Casadei Gardini, A., Lanzi, A., Mirici Cappa, F., Sacco, R., Mismas, V., Svegliati Barone, G., Schiadà, L., Farinati, F., Gazzola, A., Murer, F., Pozzan, C., Vanin, V., Rapaccini, G.L., de Matthaeis, N., Gasbarrini, A., Rinninella, E., Olivani, A., Missale, G., Biasini, E., Di Marco, M., Balsamo, C., Vavassori, E., Masotto, A., Marchetti, F., Valerio, M., Marra, F., Aburas, S., Campani, C., Dragoni, G., Borzio, F., Benvegnù, L., Festi, D., Marasco, Giovanni, Ravaioli, Federico, Giannini, E. G., Ialungo, A. M., Foschi, F. G., Dall'Aglio, A. C., Rapaccini, G. L., Garuti, Franca, Venerandi, Laura, Mega, Angela, Fiorini, Elisabetta, Lanzi, Andrea, and Balsamo, Carlo
- Subjects
medicine.medical_specialty ,Large HCC ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Survival rate ,Laser ablation ,TACE ,Univariate analysis ,business.industry ,Standard treatment ,Large HCC, Laser ablation, TACE, Oncology ,Cancer ,Hepatology ,medicine.disease ,BCLC Stage ,Oncology ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,Liver cancer ,business ,Research Paper - Abstract
// Filomena Morisco 1 , Silvia Camera 1 , Maria Guarino 1 , Raffaella Tortora 2 , Valentina Cossiga 1 , Anna Vitiello 1 , Gabriella Cordone 2 , Nicola Caporaso 1 , Giovan Giuseppe Di Costanzo 2 and Italian Liver Cancer (ITA.LI.CA) group 1 Gastroenterology Unit, Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, Italy 2 Hepatology Unit, “Cardarelli” Hospital, Naples, Italy Correspondence to: Filomena Morisco, email: filomena.morisco@unina.it Keywords: large HCC; laser ablation; TACE Received: December 13, 2017 Accepted: February 27, 2018 Published: April 03, 2018 ABSTRACT Background: Limited therapies are available for large (≥40 mm) unresectable hepatocellular carcinoma (HCC). Currently, the standard treatment with transarterial chemoembolisation (TACE) is unsatisfactory with high recurrence rate and limited effect on survival. Laser Ablation (LA) has emerged as a relatively new technique characterized by high efficacy and good safety. This study is aimed to evaluate the efficacy of LA in comparison to TACE in patients with large HCC. Methods: Eighty-two patients with a single HCC nodule ≥40 mm (BCLC stage A or B) were enrolled in this case-control study. Forty-one patients were treated with LA and 41 patients were treated with TACE. Response to therapy was evaluated according to the mRECIST criteria. Survival was calculated with Kaplan-Meier from the time of cancer diagnosis to death with values censored at the date of the last follow-up. Results: Twenty-six (63.4%) and 8 (19.5%) patients had a complete response after LA and TACE, respectively ( p 60 mm. LA resulted superior to TACE especially in nodules ranging between 51 and 60 mm in diameter, with a complete response rate post-LA and post-TACE of 75% and 14.3%, respectively ( p = 0.0133). The 36 months cumulative survival rate in patients treated with LA and TACE was 55.4% and 48.8%, respectively. The disease recurrence rates after LA and TACE were 19.5% and 75.0%, respectively. Conclusions: LA is a more effective therapeutic option than TACE in patients with solitary large HCC.
- Published
- 2018
23. Metabolic disorders across hepatocellular carcinoma in Italy
- Author
-
Morisco, F., Guarino, M., Valvano, M. R., Auriemma, F., Farinati, F., Giannini, E. G., Ciccarese, F., Tovoli, F., Rapaccini, Gian Ludovico, Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Cabibbo, G., Felder, M., Benvengu, L., Gasbarrini, Antonio, Svegliati Baroni, G., Foschi, F. G., Biasini, E., Masotto, A., Virdone, R., Marra, F., Caporaso, N., Trevisani, F., Sessa, A., Marafatto, F., Peserico, G., Pozzan, C., Brunacci, M., Moscatelli, A., Pellegatta, G., Savarino, V., Del Poggio, P., Olmi, S., De Matthaeis, Nicoletta, Balsamo, C., Vavassori, E., Roselli, P., Lauria, V., Pelecca, G., Mismas, V., Rossi, M., Attardo, S., Cavani, G., Mega, A., Rinninella, Emanuele, Ortolani, A., Bevilacqua, V., Chiara Dall'Aglio, A., Ercolani, G., Fiorini, Carlo Ettore, Casadei Gardini, A., Lanzi, Alessio, Mirici Cappa, F., Missale, G., Porro, E., Marchetti, F., Valerio, M., Affronti, A., Orlando, E., Rosa Barcellona, M., Aburas, S., Dragoni, G., Campani, C., Biselli, M., Bucci, L., Caraceni, P., Cucchetti, A., Domenicali, M., Garuti, F., Gramenzi, A., Magalotti, D., Serra, C., Granito, A., Negrini, G., Napoli, L., Piscaglia, F., Morisco, F., Guarino, M., Valvano, M. R., Auriemma, F., Farinati, F., Giannini, E. G., Ciccarese, F., Tovoli, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Cabibbo, G., Felder, M., Benvengu, L., Gasbarrini, A., Svegliati Baroni, G., Foschi, F. G., Biasini, E., Masotto, A., Virdone, R., Marra, F., Caporaso, N., Trevisani, F., Sessa, A., Marafatto, F., Peserico, G., Pozzan, C., Brunacci, M., Moscatelli, A., Pellegatta, G., Savarino, V., Del Poggio, P., Olmi, S., de Matthaeis, N., Balsamo, C., Vavassori, E., Roselli, P., Lauria, V., Pelecca, G., Mismas, V., Rossi, M., Attardo, S., Cavani, G., Mega, A., Rinninella, E., Ortolani, A., Bevilacqua, V., Chiara Dall'Aglio, A., Ercolani, G., Fiorini, E., Casadei Gardini, A., Lanzi, A., Mirici Cappa, F., Missale, G., Porro, E., Marchetti, F., Valerio, M., Affronti, A., Orlando, E., Rosa Barcellona, M., Aburas, S., Dragoni, G., Campani, C., Biselli, M., Bucci, L., Caraceni, P., Cucchetti, A., Domenicali, M., Garuti, F., Gramenzi, A., Magalotti, D., Serra, C., Granito, A., Negrini, G., Napoli, L., Piscaglia, F., Morisco, Filomena, Guarino, Maria, Valvano, Maria R., Auriemma, Francesco, Farinati, Fabio, Giannini, Edoardo G., Ciccarese, Francesca, Tovoli, Francesco, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Felder, Martina, Benvengù, Luisa, Gasbarrini, Antonio, Svegliati Baroni, Gianluca, Foschi, Francesco G., Biasini, Elisabetta, Masotto, Alberto, Virdone, Roberto, Marra, Fabio, Caporaso, Nicola, Trevisani, Franco, Sessa, Anna, Marafatto, Filippo, Peserico, Giulia, Pozzan, Caterina, Brunacci, Matteo, Moscatelli, Alessandro, Pellegatta, Gaia, Savarino, Vincenzo, Del Poggio, Paolo, Olmi, Stefano, de Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, Lauria, Valentina, Pelecca, Giorgio, Mismas, Valeria, Rossi, Margherita, Attardo, Simona, Cavani, Giulia, Mega, Andrea, Rinninella, Emanuele, Ortolani, Alessio, Bevilacqua, Vittoria, Chiara Dall'Aglio, Anna, Ercolani, Giorgio, Fiorini, Erica, Casadei Gardini, Andrea, Lanzi, Arianna, Mirici Cappa, Federica, Missale, Gabriele, Porro, Emanuela, Marchetti, Fabiana, Valerio, Matteo, Affronti, Andrea, Orlando, Emanuele, Rosa Barcellona, Maria, Aburas, Sami, Dragoni, Gabriele, Campani, Claudia, Biselli, Maurizio, Bucci, Laura, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Garuti, Francesca, Gramenzi, Annagiulia, Magalotti, Donatella, Serra, Carla, Granito, Alessandro, Negrini, Giulia, Napoli, Lucia, Piscaglia, Fabio, Valvano, Maria R, Giannini, Edoardo G, and Foschi, Francesco G
- Subjects
Oncology ,Male ,obesity ,Databases, Factual ,Hepatocellular carcinoma ,0302 clinical medicine ,Risk Factors ,Prospective cohort study ,diabetes ,Metabolic disorder ,Liver Neoplasms ,Diabetes ,hepatocellular carcinoma ,Middle Aged ,Metabolic syndrome ,Portal vein thrombosis ,Italy ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Settore MED/12 - GASTROENTEROLOGIA ,Obesity ,metabolic syndrome ,03 medical and health sciences ,Databases ,Metabolic Diseases ,Internal medicine ,medicine ,Diabetes Mellitus ,Humans ,Factual ,Aged ,Neoplasm Staging ,Retrospective Studies ,Hepatology ,business.industry ,Carcinoma ,Hepatocellular ,medicine.disease ,Survival Analysis ,BCLC Stage ,Multivariate Analysis ,diabete ,Liver function ,business - Abstract
Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed lower percentage of HCC diagnosis on surveillance (P=.021), larger tumours (P=.038), better liver function (higher percentage of Child-Pugh class A [P=.007] and MELD 
- Published
- 2018
24. External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study
- Author
-
Foschi, F. G., Conti, F., Domenicali, M., Giacomoni, P., Borghi, A., Bevilacqua, V., Napoli, L., Berardinelli, D., Altini, M., Cucchetti, A., Ercolani, G., Casadei-Gardini, A., Bellentani, S., Gastaldelli, A., Tiribelli, C., Bedogni, G., Andreone, P., Dall'Aglio, A. C., Bernardi, M., Bucchi, L., Dazzani, F., Falcini, F., Lanzi, A., Ravaioli, A., Rimini, M., Rovesti, G., Saini, G., Stefanini, G. F., Foschi, Francesco Giuseppe, Conti, Fabio, Domenicali, Marco, Giacomoni, Pierluigi, Borghi, Alberto, Bevilacqua, Vittoria, Napoli, Lucia, Berardinelli, Dante, Altini, Mattia, Cucchetti, Alessandro, Ercolani, Giorgio, Casadei-Gardini, Andrea, Bellentani, Stefano, Gastaldelli, Amalia, Tiribelli, Claudio, Bedogni, Giorgio, and Group, Bagnacavallo Study
- Subjects
medicine.medical_specialty ,Validation study ,Calibration (statistics) ,Population ,lcsh:Medicine ,Gastroenterology ,Article ,diagnostic techniques and procedures ,03 medical and health sciences ,0302 clinical medicine ,Fatty liver ,Internal medicine ,Diagnostic techniques and procedures ,medicine ,cross-sectional study ,030212 general & internal medicine ,education ,Cross-sectional study ,fatty liver ,education.field_of_study ,business.industry ,lcsh:R ,fungi ,External validation ,non-alcoholic fatty liver disease ,General Medicine ,medicine.disease ,validation study ,diagnostic techniques and procedure ,030211 gastroenterology & hepatology ,Steatosis ,business ,Non-alcoholic fatty liver disease ,Lipid Accumulation Product - Abstract
We externally validated the fatty liver index (FLI), the lipid accumulation product (LAP), the hepatic steatosis index (HSI), and the Zhejiang University index (ZJU) for the diagnosis of fatty liver (FL) and non-alcoholic fatty liver disease (NAFLD) in the general population. The validation was performed on 2159 citizens of the town of Bagnacavallo (Ravenna, Italy). Calibration was evaluated by calculating the calibration slope and intercept and by inspecting calibration plots, discrimination was evaluated using the c-statistic. The average calibration slope was 1 and the average intercept was 0 for all combinations of outcomes and indices. For the diagnosis of FL, the c-statistic was 0.85 for FLI, 0.83 for ZJU, 0.82 for HSI, and 0.80 for LAP, for the diagnosis of NAFLD, the c-statistic was 0.77 for FLI, 0.76 for ZJU, 0.75 for HSI, and 0.74 for LAP. All indices were strongly correlated with each other. In conclusion, FLI, LAP, HSI, and ZJU perform similarly well to diagnose FL and NAFLD in the Bagnacavallo population, even if FLI has a small advantage as discrimination is concerned.
- Published
- 2021
25. Common issues in the management of patients in the waiting list and after liver transplantation
- Author
-
Burra, P, Belli, L, Ginanni, Corradini, S, Volpes, R, Marzioni, M, Giannini, E, Toniutto, P, Carrai, P, Donato, F, Lanza-Galeota, A, Martini, S, Pasulo, L, Ponziani, F, Russo, F, Coppola, C, Forte, P, Mazzarelli, C, Merli, M, Montalbano, M, Picciotto, F, Rendina, M, Zanetto, A, Angeli, P, Foschi, F, Manini, M, Marzano, A, Perricone, G, Pianta, P, Tamè, M, De Maria, N, Domenicali, M, Ottobrelli, A, Picciotto, A, Ponti, L, Vizzini, G, Corradini, S, Bhoori, S, Ferri, F, Gaffuri, G, Lenci, I, Mameli, L, Morelli, M, and Piras, M. R.
- Subjects
medicine.medical_specialty ,Alcoholic liver disease ,DAAs ,HBV recurrence ,Immunosuppression ,Liver transplantation ,Antiviral Agents ,Hepatitis C, Chronic ,Humans ,Italy ,Liver Diseases, Alcoholic ,Recurrence ,Societies, Medical ,Disease Management ,Liver Transplantation ,Waiting Lists ,Hepatology ,Gastroenterology ,medicine.medical_treatment ,030230 surgery ,03 medical and health sciences ,0302 clinical medicine ,Medical ,Internal medicine ,medicine ,In patient ,Chronic ,Disease management (health) ,business.industry ,Liver Diseases ,General surgery ,Hcv recurrence ,Evidence-based medicine ,Alcoholic ,medicine.disease ,Hepatitis C ,surgical procedures, operative ,Waiting list ,030211 gastroenterology & hepatology ,Societies ,business - Abstract
The present document contains the recommendations of an expert panel of transplant hepatologists, appointed by the Italian Association for the Study of the Liver (AISF), on how to manage the most common aspects of liver transplantation: the topics covered include: new treatments for HCV in patients on the waiting list for liver transplantation; antiviral treatments in patients with HCV recurrence after liver transplantation; prophylaxis for HBV recurrence after liver transplantation; indications for liver transplantation in alcoholic liver disease; and Immunosuppressive therapy. The statements on each topic were approved by participants at the AISF Transplant Hepatologist Expert Meeting (organized by the Permanent Committee on Liver Transplantation in Mondello on 4–5 October 2015), and are graded according to the Oxford classification of levels of evidence.
- Published
- 2017
26. Transthoracic electrical bioimpedance: A non-invasive technique for the evaluation of the haemodynamic alterations in patients with liver cirrhosis
- Author
-
Dazzani, F., Micati, M., Caraceni, P., Drago, G.M., Domenicali, M., Pacilli, P., Tomassetti, V., Gelonesi, E., Trevisani, F., and Bernardi, M.
- Published
- 2005
- Full Text
- View/download PDF
27. Oxidative injury in rat fatty liver exposed to ischemia-reperfusion is modulated by nutritional status
- Author
-
Domenicali, M., Vendemiale, G., Serviddio, G., Grattagliano, I., Pertosa, A.M., Nardo, B., Principe, A., Viola, A., Trevisani, F., Altomare, E., Bernardi, M., and Caraceni, P.
- Published
- 2005
- Full Text
- View/download PDF
28. The Endocannabinoid System and Liver Diseases
- Author
-
Caraceni, P., Domenicali, M., and Bernardi, M.
- Published
- 2008
29. PORTAL VEIN ARTERIALIZATION INCREASES LIVER REGENERATION IN ACUTE LIVER FAILURE INDUCED BY EXTENDED HEPATECTOMY OR TOXIN ADMINISTRATION IN THE RAT: P122
- Author
-
Nardo, B., Caraceni, P., Puviani, L., Montalti, R., Bertelli, R., Beltempo, P., Pacilè, V., Licursi, M., Pertosa, A. M., Domenicali, M., Pariali, M., Bernardi, M., and Cavallari, A.
- Published
- 2005
30. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study
- Author
-
Caputo, F., Addolorato, G., Lorenzini, F., Domenicali, M., Greco, G., del RE, A., Gasbarrini, G., Stefanini, G.F., and Bernardi, M.
- Published
- 2003
- Full Text
- View/download PDF
31. PROLONGATION OF THE QT INTERVAL IN CIRRHOSIS: ROLE OF PORTAL HYPERTENSION
- Author
-
Valeriano, V., Trevisani, F., Merli, M., Mainquà, P., Lionetti, R., Domenicali, M., Riggio, O., and Bernardi, M.
- Published
- 1999
32. STATE AND TRAIT ANXIETY AND DEPRESSION IN PATIENTS AFFECTED BY CHRONIC LIVER DISEASE: A CASE CONTROL STUDY
- Author
-
Addolorato, G., Caputo, F., Dall'Aglio, C., Domenicali, M., Stefanini, G. F., Gasbarrini, G., Trevisani, F., and Bernardi, M.
- Published
- 1999
33. REACTIVE OXYGEN SPECIES GENERATION DURING POST-ISCHEMIC REPERFUSION IN NORMAL AND FATTY LIVERS: ROLE OF NUTRITIONAL STATUS
- Author
-
Nardo, B., Domenicali, M., Caraceni, P., Turi, P., Catena, F., Pasini, P., Roda, A., Bernardi, M., and Cavallari, A.
- Published
- 1999
34. MITOCHONDRIAL INJURY CONTRIBUTES TO ENAHCE ISCHEMIA-REPERFUSION INJURY IN RAT FATTY LIVER
- Author
-
Caraceni, P., Grattagliano, I., Domenicali, M., Nardo, B., Dall'Agata, M., Trevisani, F., Vendemiale, G. L., Altomare, E., Cavallari, A., and Bernardi, M.
- Published
- 1999
35. The residual native albumin predicts albumin dysfunction and outcomes in hospitalized cirrhotic patients with acute decompensation or acute-on-chronic liver failure
- Author
-
Baldassarre, M., primary, Naldi, M., additional, Bartoletti, M., additional, Antognoli, A., additional, Laggetta, M., additional, Gagliardi, M., additional, Zaccherini, G., additional, Iannone, G., additional, Pratelli, D., additional, Domenicali, M., additional, Waterstradt, K., additional, Bartolini, M., additional, Trevisani, F., additional, Bernardi, M., additional, and Caraceni, P., additional
- Published
- 2019
- Full Text
- View/download PDF
36. Predictors of nosocomial acute-on-chronic liver failure for the risk stratification of patients with cirrhosis admitted to hospital with acute decompensation
- Author
-
Zaccherini, G., primary, Baldassarre, M., additional, Bartoletti, M., additional, Berardi, S., additional, Tamè, M., additional, Napoli, L., additional, Siniscalchi, A., additional, Fabbri, A., additional, Marconi, L., additional, Antognoli, A., additional, Iannone, G., additional, Domenicali, M., additional, Viale, P., additional, Trevisani, F., additional, Bernardi, M., additional, and Caraceni, P., additional
- Published
- 2019
- Full Text
- View/download PDF
37. RELATIONSHIP BETWEEN OXIDATIVE STRESS AND AUTONOMIC NEUROPATHY IN LIVER CIRRHOSIS
- Author
-
Simoncini, M., Trevisani, F., Mainquà, P., Sica, G., Caraceni, P., De Notariis, S., Domenicali, M., Angelini, G. R., Guarnieri, C., and Bernardi, M.
- Published
- 1998
38. Evidence of oxidative imbalance in long-term liver transplant patients
- Author
-
Trevisani, F., Caraceni, P., Simoncini, M., Micati, M., Domenicali, M., Dazzani, F., Zambruni, A., Stefanelli, C., Grazi, G., Nardo, B., Guarnieri, C., and Bernardi, M.
- Published
- 2002
- Full Text
- View/download PDF
39. WP1/01 FASTING IS A MAIN DETERMINANT OF ISCHEMIA-REPERFUSION INJURY IN FATTY LIVERS
- Author
-
Caraceni, P., Nardo, B., Domenicali, M., Turi, P., Simoncini, M., Trevisani, F., Montanaro, L., Cavallari, A., and Bernardi, M.
- Published
- 1997
40. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study
- Author
-
Piscaglia, Fabio, Svegliati Baroni, Gianluca, Barchetti, Andrea, Pecorelli, Anna, Marinelli, Sara, Tiribelli, Claudio, Bellentani, Stefano, Bernardi M, Biselli M, Bernardi M, Biselli M, Caraceni P, Domenicali M, Garuti F, Gramenzi A, Lenzi B, Magalotti D, Cescon M, Ravaioli M, Del Poggio P, Olmi S, Rapaccini GL, Balsamo C, Di Nolfo MA, Vavassori E, Alberti A, Benvegnù L, Gatta A, Giacomin A, Vanin V, Pozzan C, Maddalo G, Giampalma E, Cappelli A, Golfieri R, Mosconi C, Renzulli M, Roselli P, Dell'Isola S, Ialungo AM, Risso D, Marenco S, Sammito G, Bruzzone L, Bosco G, Grieco A, Pompili M, Rinninella E, Siciliano M, Chiaramonte M, Guarino M, Cammà C, Maida M, Costantino A, Barcellona MR, Schiadà L, Gemini S, Lanzi A, Stefanini GF, Dall'Aglio AC, Cappa FM, Suzzi A, Mussetto A, Treossi O, Missale G, Porro E, Mismas V, Vivaldi C, Bolondi L, Zoli M, Granito A, Malagotti D, Tovoli F, Trevisani F, Venerandi L, Brandi G, Cucchetti A, Bugianesi E, Vanni E, Mezzabotta L, Cabibbo G, Petta S, Fracanzani A, Fargion S, Marra F, Fani B, Biasini E, Sacco R, CAPORASO, NICOLA, Colombo M, D'Ambrosio R, Crocè LS, Patti R, Giannini EG, Loria P, Lonardo A, Baldelli E, Miele L, Farinati F, Borzio M, Dionigi E, Soardo G, Caturelli E, Ciccarese F, Virdone R, Affronti A, Foschi FG, Borzio F., MORISCO, FILOMENA, Piscaglia, Fabio, Svegliati Baroni, Gianluca, Barchetti, Andrea, Pecorelli, Anna, Marinelli, Sara, Tiribelli, Claudio, Bellentani, Stefano, Bernardi M, Biselli M, Bernardi, M, Biselli, M, Caraceni, P, Domenicali, M, Garuti, F, Gramenzi, A, Lenzi, B, Magalotti, D, Cescon, M, Ravaioli, M, Del Poggio, P, Olmi, S, Rapaccini, Gl, Balsamo, C, Di Nolfo, Ma, Vavassori, E, Alberti, A, Benvegnù, L, Gatta, A, Giacomin, A, Vanin, V, Pozzan, C, Maddalo, G, Giampalma, E, Cappelli, A, Golfieri, R, Mosconi, C, Renzulli, M, Roselli, P, Dell'Isola, S, Ialungo, Am, Risso, D, Marenco, S, Sammito, G, Bruzzone, L, Bosco, G, Grieco, A, Pompili, M, Rinninella, E, Siciliano, M, Chiaramonte, M, Guarino, M, Cammà, C, Maida, M, Costantino, A, Barcellona, Mr, Schiadà, L, Gemini, S, Lanzi, A, Stefanini, Gf, Dall'Aglio, Ac, Cappa, Fm, Suzzi, A, Mussetto, A, Treossi, O, Missale, G, Porro, E, Mismas, V, Vivaldi, C, Bolondi, L, Zoli, M, Granito, A, Malagotti, D, Tovoli, F, Trevisani, F, Venerandi, L, Brandi, G, Cucchetti, A, Bugianesi, E, Vanni, E, Mezzabotta, L, Cabibbo, G, Petta, S, Fracanzani, A, Fargion, S, Marra, F, Fani, B, Biasini, E, Sacco, R, Morisco, Filomena, Caporaso, Nicola, Colombo, M, D'Ambrosio, R, Crocè, L, Patti, R, Giannini, Eg, Loria, P, Lonardo, A, Baldelli, E, Miele, L, Farinati, F, Borzio, M, Dionigi, E, Soardo, G, Caturelli, E, Ciccarese, F, Virdone, R, Affronti, A, Foschi, Fg, Borzio, F., Fabio Piscagliaxxx, Gianluca Svegliati-Baroni, Andrea Barchetti, Anna Pecorellixxx, Sara Marinellixxx, Claudio Tiribelli, and, Stefano Bellentani, on behalf of the HCC-NAFLD Italian Study Group [, Mauro Bernardi, Maurizio Biselli, Paolo Caraceni, Marco Domenicali, Francesca Garuti, Annagiulia Gramenzi, Barbara Lenzi, Donatella Magalotti, Matteo Cescon, Matteo Ravaioli, Emanuela Giampalma, Rita Golfieri, Cristina Mosconi, Luigi Bolondi, Marco Zoli, Alessandro Granito, Francesco Tovoli, Franco Trevisani, Laura Venerandi, Giovanni Brandi, Alessandro Cucchetti, ], DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE, DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE, Facolta' di MEDICINA e CHIRURGIA, AREA MIN. 06 - Scienze mediche, Da definire, Croce', Saveria, and HCC NAFLD Italian Study, Group
- Subjects
Male ,Cirrhosis ,Survival ,Chronic liver disease ,Gastroenterology ,0302 clinical medicine ,Non-alcoholic Fatty Liver Disease ,Nonalcoholic fatty liver disease ,80 and over ,Prospective Studies ,Chronic ,Prospective cohort study ,Aged, 80 and over ,Medicine (all) ,Liver Neoplasms ,hepatocellular carcinoma ,Middle Aged ,Hepatitis C ,Liver Neoplasm ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Competing risk analysi ,030211 gastroenterology & hepatology ,Female ,Non Alcoholic SteatoHepatitis=NASH ,Human ,medicine.medical_specialty ,Aged ,Carcinoma, Hepatocellular ,Hepatitis C, Chronic ,Humans ,Hepatology ,Competing risk analysis ,Milan criteria ,03 medical and health sciences ,Internal medicine ,medicine ,Survival rate ,business.industry ,Settore MED/09 - MEDICINA INTERNA ,Carcinoma ,nutritional and metabolic diseases ,Hepatocellular ,medicine.disease ,digestive system diseases ,Nonalcoholic fatty liver disease, hepatocellular carcinoma, clinical patterns ,business ,clinical patterns - Abstract
none 31 no Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome and may evolve into hepatocellular carcinoma (HCC). Only scanty clinical information is available on HCC in NAFLD. The aim of this multicenter observational prospective study was to assess the clinical features of patients with NAFLD-related HCC (NAFLD-HCC) and to compare them to those of hepatitis C virus (HCV)-related HCC. A total of 756 patients with either NAFLD (145) or HCV-related chronic liver disease (611) were enrolled in secondary care Italian centers. Survival was modeled according to clinical parameters, lead-time bias, and propensity analysis. Compared to HCV, HCC in NAFLD patients had a larger volume, showed more often an infiltrative pattern, and was detected outside specific surveillance. Cirrhosis was present in only about 50% of NAFLD-HCC patients, in contrast to the near totality of HCV-HCC. Regardless of tumor stage, survival was significantly shorter (P = 0.017) in patients with NAFLD-HCC, 25.5 months (95% confidence interval 21.9-29.1), than in those with HCV-HCC, 33.7 months (95% confidence interval 31.9-35.4). To eliminate possible confounders, a propensity score analysis was performed, which showed no more significant difference between the two groups. Additionally, analysis of patients within Milan criteria submitted to curative treatments did not show any difference in survival between NAFLD-HCC and HCV-HCC (respectively, 38.6 versus 41.0 months, P = nonsignificant) CONCLUSIONS: NAFLD-HCC is more often detected at a later tumor stage and could arise also in the absence of cirrhosis, but after patient matching, it has a similar survival rate compared to HCV infection; a future challenge will be to identify patients with NAFLD who require more stringent surveillance in order to offer the most timely and effective treatment. Fabio Piscagliaxxx; Gianluca Svegliati-Baroni; Andrea Barchetti; Anna Pecorellixxx; Sara Marinellixxx; Claudio Tiribelli; and; Stefano Bellentani; on behalf of the HCC-NAFLD Italian Study Group [;Mauro Bernardi; Maurizio Biselli; Paolo Caraceni; Marco Domenicali; Francesca Garuti; Annagiulia Gramenzi; Barbara Lenzi; Donatella Magalotti; Matteo Cescon; Matteo Ravaioli; Emanuela Giampalma; Rita Golfieri; Cristina Mosconi; Luigi Bolondi; Marco Zoli; Alessandro Granito; Francesco Tovoli; Franco Trevisani; Laura Venerandi; Giovanni Brandi; Alessandro Cucchetti;] Fabio Piscagliaxxx; Gianluca Svegliati-Baroni; Andrea Barchetti; Anna Pecorellixxx; Sara Marinellixxx; Claudio Tiribelli; and; Stefano Bellentani; on behalf of the HCC-NAFLD Italian Study Group [;Mauro Bernardi; Maurizio Biselli; Paolo Caraceni; Marco Domenicali; Francesca Garuti; Annagiulia Gramenzi; Barbara Lenzi; Donatella Magalotti; Matteo Cescon; Matteo Ravaioli; Emanuela Giampalma; Rita Golfieri; Cristina Mosconi; Luigi Bolondi; Marco Zoli; Alessandro Granito; Francesco Tovoli; Franco Trevisani; Laura Venerandi; Giovanni Brandi; Alessandro Cucchetti;]
- Published
- 2016
41. Novel strategies to treat alcohol dependence with sodium oxybate according to clinical practice
- Author
-
Caputo F, Mirijello A, Cibin M, Mosti A, Mauro CECCANTI, Domenicali M, Bernardi M, Maremmani I, Addolorato G, Smo, Twentieth Anniversary Of The Use Of In Italy Group, Caputo F, Mirjiello A, Cibin M, Mosti A, Ceccanti M, Domenicali M, Bernardi M, Maremmani I, Addolorato G, and for the 'Twentieth anniversary of the use of SMO in Italy' Group
- Subjects
therapy ,CLINICAL PRACTICE ,ALCOHOL RELATED DISEASE ,Alcohol dependence ,Alcoholism ,Humans ,Italy ,Practice Guidelines as Topic ,Sodium Oxybate ,Surveys and Questionnaires ,SODIUM OXYBATE ,NO ,Treatment ,Alcohol dependence, Treatment, Sodium oxybate, Clinical practice - Abstract
OBJECTIVE: The treatment of alcohol dependence (AD) with sodium oxybate (SMO) was introduced in Italy and Austria more than 20 years and 15 years ago respectively,and it is now widely employed. In addition to the data obtained from clinical trials, little information is available on specific clinical practices. Thus, the aim of this study was to present and discuss the results of a consensus meeting held after twenty years of using SMO in clinical practice in Italy. MATERIALS AND METHODS: A validated questionnaire study was conducted to investigate the modalities of treatment of AD with SMO currently used in Italy. A group of four refereesfirst drew up the questionnaire which was distributed to fifty experts in the field of alcohol use disorders. The questionnaire consisted of 125 items with five different modalities of response and two or three answer possibilities. RESULTS: The results of this survey showed a broad consensus on some issues regarding, for example, the duration of treatment, and the dose regimen of the drug; however, some aspects of the treatment of AD with SMO still remain controversial. CONCLUSIONS: This is the first consensus study investigating the use of SMO for the treatment of AD through the opinions gained in over twenty years of clinical practice provided by fifty Italian expert clinicians. A consensus on good practice for the correct administration of SMO has clearly emerged; these opinions, along with those derived from previous clinical investigations, will help physicians to use SMO in a betterway. However, some issues remain controversial, and others remain unresolved.
- Published
- 2015
42. Outcome of bacterial infections complicated or not by acute-on-chronic liver failure in patients with cirrhosis admitted to hospital for acute decompensation
- Author
-
Bartoletti, M., primary, Baldassarre, M., additional, Domenicali, M., additional, Rinaldi, M., additional, Giannella, M., additional, Lewis, R., additional, Tufoni, M., additional, Zaccherini, G., additional, Tamé, M., additional, Napoli, L., additional, Pavarin, R.M., additional, Berardi, S., additional, Ballardini, G., additional, Bernardi, M., additional, Viale, P., additional, and Caraceni, P., additional
- Published
- 2018
- Full Text
- View/download PDF
43. Bacterial infections with and without acute-on-chronic liver failure in patients with cirrhosis and acute decompensation: Risk factors and outcome
- Author
-
Bartoletti, M., primary, Baldassarre, M., additional, Domenicali, M., additional, Lewis, R., additional, Giannella, M., additional, Rinaldi, M., additional, Tufoni, M., additional, Zaccherini, G., additional, Tamè, M., additional, Berardi, S., additional, Napoli, L., additional, Pavarin, F.M., additional, Angela, F., additional, Trevisani, F., additional, Bernardi, M., additional, Viale, P., additional, and Caraceni, P., additional
- Published
- 2018
- Full Text
- View/download PDF
44. A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection
- Author
-
Cassini, R, De Mitri MS, Gibellini, Davide, Urbinati, L, Bagaglio, S, Morsica, G, Domenicali, M, Verucchi, G, Bernardi, M., Cassini R, De Mitri MS, Gibellini D, Urbinati L, Bagaglio S, Morsica G, Domenicali M, Verucchi G, and Bernardi M.
- Subjects
Adult ,Male ,Hepatitis B virus ,LIVER ,Genotype ,DNA Mutational Analysis ,Molecular Sequence Data ,HIV Infections ,Genome, Viral ,Virus Replication ,HBV ,Humans ,Amino Acid Sequence ,OCCULT HBV ,Retrospective Studies ,Hepatitis B Surface Antigens ,Base Sequence ,PBMC ,occult HBV infection ,virus diseases ,HIV ,Sequence Analysis, DNA ,Middle Aged ,Viral Load ,Hepatitis B ,digestive system diseases ,Codon, Nonsense ,DNA, Viral ,Leukocytes, Mononuclear ,Female ,Sequence Alignment - Abstract
To characterize occult HBV infection (OHB) in different compartments of HIV+ individuals. This retrospective study involved 38 consecutive HIV+ patients; 24 HBsAg negative (HBV-) and 14 HBsAg positive (HBV+). OHB was assessed in serum samples, liver tissue (LT) and peripheral blood mononuclear cells (PBMC) by genomic amplification of the partial S, X and precore/core regions. HBV genomic analysis was inferred by direct sequencing of PCR products. The intracellular HBV-DNA was measured by a quantitative real-time PCR. HBV+ patients were used as a control for HBV replication and genomic profile. In HBV- patients, HBV-DNA was undetectable in all serum samples, while it was found positive in 7/24 (29%) LT in which genotype D prevailed (57%). HBV-DNA was found in 6/7 (86%) PBMC of occult-positive and none of occult-negative LT. Significantly lower HBV-DNA load was present in both compartments in OHB+ with respect to the HBV+ group (LT: P = 0.002; PBMC: P = 0.026). In the occult-positive cases, HBV replication was significantly higher in LT than in PBMC (P = 0.028). A hyper-mutated S gene in PBMC and a nucleotide mutation at position C695 in LT that produces a translational stop codon at amino acid 181 of the HBs gene characterized OHB. In this group of HIV+ persons, OHB is frequent and exhibits lower replication levels than chronic HBV in the different compartments examined. HBV-DNA detection in PBMC may offer a useful tool to identify OHB in serum-negative cases. The novel HBs gene stop codon found in LT could be responsible for reduced production leading to undetectability of HBsAg.
- Published
- 2013
45. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis
- Author
-
Gustot, T, Fernandez, J, Garcia, E, Morando, F, Caraceni, P, Alessandria, C, Laleman, W, Trebicka, J, Elkrief, L, Hopf, C, Solis-Munoz, P, Saliba, F, Zeuzem, S, Albillos, A, Benten, D, Montero-Alvarez, JL, Chivas, MT, Concepcion, M, Cordoba, J, McCormick, A, Stauber, R, Vogel, W, de Gottardi, A, Welzel, TM, Domenicali, M, Risso, A, Wendon, J, Deulofeu, C, Angeli, P, Durand, F, Pavesi, M, Gerbes, A, Jalan, R, Moreau, R, Gines, P, Bernardi, M, and Arroyo, V
- Subjects
610 Medicine & health - Abstract
Acute-on-chronic liver failure (ACLF) is characterized by acute decompensation (AD) of cirrhosis, organ failure(s), and high 28-day mortality. We investigated whether assessments of patients at specific time points predicted their need for liver transplantation (LT) or the potential futility of their care. We assessed clinical courses of 388 patients who had ACLF at enrollment, from February through September 2011, or during early (28-day) follow-up of the prospective multicenter European Chronic Liver Failure (CLIF) ACLF in Cirrhosis study. We assessed ACLF grades at different time points to define disease resolution, improvement, worsening, or steady or fluctuating course. ACLF resolved or improved in 49.2%, had a steady or fluctuating course in 30.4%, and worsened in 20.4%. The 28-day transplant-free mortality was low-to-moderate (6%-18%) in patients with nonsevere early course (final no ACLF or ACLF-1) and high-to-very high (42%-92%) in those with severe early course (final ACLF-2 or -3) independently of initial grades. Independent predictors of course severity were CLIF Consortium ACLF score (CLIF-C ACLFs) and presence of liver failure (total bilirubin 12 mg/dL) at ACLF diagnosis. Eighty-one percent had their final ACLF grade at 1 week, resulting in accurate prediction of short- (28-day) and mid-term (90-day) mortality by ACLF grade at 3-7 days. Among patients that underwent early LT, 75% survived for at least 1 year. Among patients with 4 organ failures, or CLIF-C ACLFs >64 at days 3-7 days, and did not undergo LT, mortality was 100% by 28 days. Conclusions: Assessment of ACLF patients at 3-7 days of the syndrome provides a tool to define the emergency of LT and a rational basis for intensive care discontinuation owing to futility. (Hepatology 2015;62:243-252)
- Published
- 2015
- Full Text
- View/download PDF
46. Portal Vein Arterialization for the Treatment of Post Resection Acute Liver Failure in the Rat
- Author
-
Nardo, B., Puviani, L., Caraceni, P., Pacilè, V., Bertelli, R., Beltempo, P., Cavallari, G., Chieco, P., Pariali, M., Pertosa, A.M., Angiolini, G., Domenicali, M., Neri, F., Prezzi, D., Tsivian, M., Bernardi, M., and Cavallari, A.
- Published
- 2006
- Full Text
- View/download PDF
47. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population
- Author
-
CUCCHETTI, ALESSANDRO, TREVISANI, FRANCO, CESCON, MATTEO, ERCOLANI, GIORGIO, ZOLI, MARCO, PINNA, ANTONIO DANIELE, GRAMENZI, ANNAGIULIA, Farinati F., Poggio P. D., Rapaccini G., Nolfo M. A., Benvegnù L., Borzio F., Giannini E. G., Caturelli E., Chiaramonte M., BERNARDI, MAURO, Buccione D., CARACENI, PAOLO, Domenicali M., Erroi V., Fatti G., Frigerio M., Santi V., Magalotti D., Balsamo C., DI MARCO, MARIACRISTINA, Vavassori E., Gilardoni L., Mattiello M., Alberti A., Gatta A., Gios M., Cazzagon N., Giacomin A., Pozzan C., Sergio A., Vanin V., Giampalma E., Golfieri R., Mosconi C., Renzulli M., Ghittoni G., Roselli P., Bodini G., Corbo M., Savarino V., DOMENICALI, MARCO, Cucchetti A., Trevisani F., Cescon M., Ercolani G., Farinati F., Poggio P.D., Rapaccini G., Nolfo M.A., Benvegnù L., Zoli M., Borzio F., Giannini E.G., Caturelli E., Chiaramonte M., Pinna A.D., Bernardi M., Buccione D., Caraceni P., Domenicali M., Erroi V., Fatti G., Frigerio M., Gramenzi A., Santi V., Magalotti D., Balsamo C., Di Marco M., Vavassori E., Gilardoni L., Mattiello M., Alberti A., Gatta A., Gios M., Cazzagon N., Giacomin A., Pozzan C., Sergio A., Vanin V., Giampalma E., Golfieri R., Mosconi C., Renzulli M., Ghittoni G., Roselli P., Bodini G., Corbo M., and Savarino V.
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cost effectiveness ,Cost-Benefit Analysis ,medicine.medical_treatment ,Population ,COST-EFFECTIVENESS ANALYSIS ,Liver transplantation ,Risk Factors ,Internal medicine ,SURVEILLANCE ,medicine ,Humans ,HEPATOCELLULAR CARCINOMA ,Intensive care medicine ,education ,Survival rate ,CIRRHOSIS ,Aged ,Aged, 80 and over ,education.field_of_study ,Hepatology ,Relative survival ,business.industry ,Incidence ,Liver Neoplasms ,Odds ratio ,Middle Aged ,Prognosis ,medicine.disease ,Markov Chains ,Survival Rate ,Italy ,Population Surveillance ,Female ,business ,Liver cancer ,Incremental cost-effectiveness ratio - Abstract
BACKGROUND AND AIMS: It was recently shown that semi-annual surveillance for hepatocellular carcinoma (HCC) in cirrhotic patients provides a prognostic advantage over the annual program; however, its cost-effectiveness (CE) in the general cirrhotic population still needs to be defined. METHODS: A Markov model was built to compare CE of these two strategies, considering literature results and treatment modalities of 918 cirrhotic patients from the Italian Liver Cancer (ITA.LI.CA) database. RESULTS: Results from the Markov model suggest that, compared to annual surveillance, semi-annual surveillance leads to a gain in quality-adjusted life expectancy, in an unselected cirrhotic population, of 1.35 quality-adjusted life-months (QALMs) over 10 years since surveillance start in compensated patients, and of 0.73 QALMs in decompensated patients. Semi-annual surveillance was more cost-effective in compensated than in decompensated cirrhosis, with an incremental CE ratio (ICER) of 1997 and 3814€/QALM, respectively. In compensated cirrhosis, semi-annual surveillance was more cost-effective than the annual program when the annual HCC incidence was ≥3.2% and the relative survival gain after cancer diagnosis was ≥20% with respect to the annual program. In decompensated cirrhosis, semi-annual surveillance was cost-effective in patients amenable to liver transplantation. In both groups, CE of semi-annual surveillance improved with the increase of annual incidence and the survival benefit obtainable with HCC treatment. CONCLUSIONS: Both surveillance strategies for HCC in cirrhotic patients can be recommended, according to the individual risk profile for HCC occurrence and the expected survival gain obtainable after tumor diagnosis and therapy.
- Published
- 2012
48. Liver transplantation for hepatocellular carcinoma in clinical practice: the lesson from a 20-year multicentre experience in Italy
- Author
-
Farinati Fabio, Giacomin Anna, Vanin Veronica, Sergio Adriana, Burra Patrizia, Cillo Umberto, Di Nolfo Annamaria, Del Poggio Paolo, Benvegnu Luisa, Zoli Marco, Borzio Franco, Giannini Edoardo, Caturelli Eugenio, Cazzagon Nora, Rapaccini Gian Ludovico, Trevisani Franco, for the Italian Liver Cancer (ITA. LI. CA) group, Andreone P, Bernardi M, Biselli M, Caraceni P, di Micoli A, Domenicali M, Magalotti D, Cappa FM, Santi V, Zambruni A, Balsamo C, Di Marco M, Vavassori E, Gilardoni L, Mattiello M, Alberti A, Gatta A, Gios M, Molaro M, Sala M, Savarino V, Risso D, Ghittoni G, Roselli P, Grazi GL, Nardo B, Ravaioli M, Pinna AD, Giampalma E, Golfieri R, Farinati Fabio, Giacomin Anna, Vanin Veronica, Sergio Adriana, Burra Patrizia, Cillo Umberto, Di Nolfo Annamaria, Del Poggio Paolo, Benvegnu Luisa, Zoli Marco, Borzio Franco, Giannini Edoardo, Caturelli Eugenio, Cazzagon Nora, Rapaccini Gian Ludovico, Trevisani Franco, for the Italian Liver Cancer (ITA.LI.CA) group [.., Andreone P, Bernardi M, Biselli M, Caraceni P, di Micoli A, Domenicali M, Magalotti D, Cappa FM, Santi V, Zambruni A, Balsamo C, Di Marco M, Vavassori E, Gilardoni L, Mattiello M, Alberti A, Gatta A, Gios M, Molaro M, Sala M, Savarino V, Risso D, Ghittoni G, Roselli P, Grazi GL, Nardo B, Ravaioli M, Pinna AD, Giampalma E, Golfieri R, and ]
- Subjects
Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,medicine.medical_treatment ,Liver transplantation ,Guideline ,Gastroenterology ,Internal medicine ,Carcinoma ,Medicine ,Humans ,guidelines ,neoplasms ,Selection (genetic algorithm) ,Aged ,Hepatology ,business.industry ,General surgery ,HEPATOCELLULAR CARCINOMA ,LIVER TRANSPLANTATION ,Guidelines ,Evidence-based approach ,Patient Selection ,Liver Neoplasms ,hepatocellular carcinoma ,evidence-based approach ,liver transplantation ,Middle Aged ,medicine.disease ,Prognosis ,digestive system diseases ,Liver Transplantation ,Neoplasm Proteins ,Clinical Practice ,Transplantation ,Treatment Outcome ,Italy ,Hepatocellular carcinoma ,Practice Guidelines as Topic ,Female ,Guideline Adherence ,alpha-Fetoproteins ,business ,Epidemiologic Methods - Abstract
INTRODUCTION: Hepatocellular carcinoma (HCC) is an established indication for liver transplantation (LT), but the selection criteria and priority are still debated. AIMS: To ascertain the number and features of patients with HCC who undergo transplantation in a Western country, the number of patients eligible for LT according to the American Association for the Study of Liver Diseases (AASLD) guidelines, the number of patients who actually undergo transplantation and whether adherence affects survival. METHODS: This is a retrospective analysis from a multicentre Italian database of 2042 cases of HCC, recruited prospectively and consecutively. Kaplan-Meier (log rank) and Cox multivariate analysis estimated survival. RESULTS: Patients who had undergone transplantation (50, 2.5%, with no change over time) had a median survival of 133 months, significantly influenced by the number of lesions and alpha-fetoprotein levels, which were found to be independent predictors of survival on multivariate analysis. Milan criteria were fulfilled in 68%, impacting on survival, whereas 48% fulfilled AASLD guidelines, without such an impact. Two hundred and twenty-eight (11%) patients were eligible for LT according to AASLD; in this group, alpha-fetoprotein levels and Child-Pugh class were independent predictors of survival. CONCLUSION: Among patients with HCC, those undergoing LT represent a small minority; even fewer (1%) are those who undergo transplantation according to AASLD guidelines, adherence to which only marginally affects survival. Overall, LT impact on HCC patients' treatment is very limited
- Published
- 2011
49. Factors that affect efficacy of ultrasound surveillance for early-stage hepatocellular carcinoma in patients with cirrhosis
- Author
-
Del Poggio, P, Olmi, S, Ciccarese, F, Di Marco, M, Rapaccini, Gl, Benvegnù, L, Borzio, F, Farinati, F, Zoli, M, Giannini, Eg, Caturelli, E, Chiaramonte, M, Trevisani, F., Bernardi, M. l., Biselli, M. l., Caraceni, P. l., Cucchetti, A. l., Domenicali, M. l., Frigerio, M. l., Gramenzi, A. l., Garuti, F. l., Lenzi, B. l., Magalotti, D. l., Ravaioli, M. l., Giacomin, A. m., Vanin, V. m., Pozzan, C. m., Maddalo, G. m., Alberti, A. n., Gatta, A. n., Gios, M. n., Cappelli, A. o., and Giampalma, E.
- Published
- 2014
50. Management of malnutrition in patients with cirrhosis requires a personalized educational approach
- Author
-
Giannone, F.A., primary, Domenicali, M., additional, Baldassarre, M., additional, De Pasquale, P., additional, Boffelli, S., additional, Laggetta, M., additional, Biselli, M., additional, Bernardi, M., additional, and Caraceni, P., additional
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.